Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.41 |
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.39 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11402385 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL9097783 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL146225 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL1931553 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL6686083 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL24091301 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL18578073 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL7062492 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL6480248 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 | |
| SCHEMBL28616573 | 1.00 | TP53 (0.48) | TP53SMPD1GPR84FDPSFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338783-A | Composition for controlling arthropods | 宝洁公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4373280-A1 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | The Procter & Gamble Company (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240157379-A1 | LIQUID DISPENSING PRODUCT HAVING A SPRAY DISPENSER | THE PROCTER & GAMBLE COMPANY | 2024-05-16 | — | — | US | disclosed |
| WO-2024102782-A1 | LIQUID DISPENSING PRODUCT HAVING A SPRAY DISPENSER | THE PROCTER & GAMBLE COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-117693294-A | Composition for controlling arthropods | 宝洁公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240041053-A1 | LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY | 2024-02-08 | — | — | US | disclosed |
| US-20240041052-A1 | LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY | 2024-02-08 | — | — | US | disclosed |
| WO-2024026431-A1 | LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230320365-A1 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | PROCTER & GAMBLE (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023114952-A1 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | THE PROCTER & GAMBLE COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023004404-A1 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | THE PROCTER & GAMBLE COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |
| US-8524276-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH LLC (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2371357-A1 | Oral formulations and lipophilic salts of methylnaltrexone | Wyeth LLC (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011112816-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-0981361-A4 | METHOD OF TREATING SEPSIS | SMITHKLINE BEECHAM CORP (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6413510-B1 | CHEMOKINES | SMITHKLINE BEECHAM CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-6042821-A | TREATING SEPSIS USING CHEMOKINES WHICH ARE A PROTEIN OR POLYPEPTIDE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0981361-A1 | METHOD OF TREATING SEPSIS | Smithkline Beecham (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-1998048828-A1 | METHOD OF TREATING SEPSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | TP53 4523/4885SMPD1 2585/4885GPR84 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.